Dana-farber Cancer Institute
Clinical trials sponsored by Dana-farber Cancer Institute, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Prehab for rectal cancer: could a simple program boost recovery? Results expected Sep 2026 (estimated)
- New hope for aggressive uterine cancer: targeted drug trial shows promise Results expected Sep 2026 (estimated)
- Exercise may tame steroid side effects in stem cell transplant patients Results expected Sep 2026 (estimated)
- Acupuncture needles take on chemo nerve pain in major trial Results expected Sep 2026 (estimated)
- Zoom bike workouts could help young brain tumor survivors get fit and think sharper Results expected Sep 2026 (estimated)
-
Experimental drug BVD-523 tested for rare eye cancer, but trial stopped early
Disease control Stopped earlyThis study tested a drug called BVD-523 (Ulixertinib) in 13 people with advanced uveal melanoma, a rare eye cancer that has spread. The drug works by blocking certain proteins that help cancer grow. The trial was terminated early, so results are limited and it's unclear how well …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immunotherapy combo studied for rare lung cancer, trial stopped early
Disease control Stopped earlyThis study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy combo studied for advanced lung cancer, but trial cut short
Disease control Stopped earlyThis study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising combo for brain metastases hits early snag: trial ends early
Disease control Stopped earlyThis phase 2 study tested a drug called GDC-0084 combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. Unfortunately, the trial was terminated …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Promising breast cancer drug trial stopped early
Disease control Stopped earlyThis study tested a drug called abemaciclib in 27 people with a specific type of advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the cancer's growth. The trial was terminated early, so results are limi…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising drug combo for Hard-to-Treat breast cancer falls short in early trial
Disease control Stopped earlyThis phase 2 trial tested the drug neratinib, alone or with fulvestrant, in 21 people with HER2-positive, ER-positive metastatic breast cancer. The study aimed to see if the combination could slow cancer growth. However, the trial was terminated early, meaning we have limited dat…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy shows promise for tough bladder cancer
Disease control Stopped earlyThis study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC